2nd Year PE Analyst Seeking Advice
Hey all: looking for some advice on next steps. I'm a 2nd year analyst at a lower middle market PE firm (~$1.5B AUM) based in the Mid-Atlantic. I am personally focused solely on HC at my current fund, so my deal experience is pretty niche but deep.
Over the past ~2 years I've closed 6 transactions (2 platforms, 4 add-ons) across special education, home health & hospice, neurorehabilitation, and pharma commercialization. Platform deals ranged from $100-200M TEV. I've had a pretty hands-on experience as an analyst, and analysts are involved across the full deal lifecycle. My modeling skills are OK, and feel pretty competent at other aspects of the job.
Background is a non-target undergrad (solid undergrad business school, ~3.7 GPA, finance major) with a PE internship (Chicago, LMM) the summer before joining my current firm full time.
Thinking about my next move and open to a few different paths — another PE seat (ideally associate level at another LMM fund), corp dev, strategic finance at a growth-stage company, or even something more entrepreneurial. Not married to healthcare but it's obviously where my network and knowledge base are strongest.
Appreciate any advice or DMs. Happy to return the favor if anyone has questions about healthcare PE or LMM deal experience.
Based on the most helpful WSO content, here’s a breakdown of advice tailored to your situation:
1. Leverage Your Healthcare Niche
2. Positioning for LMM PE Associate Roles
3. Exploring Corp Dev or Strategic Finance
4. Entrepreneurial Path
5. Improving Your Modeling Skills
6. Next Steps
Your healthcare niche and deal experience position you well for a variety of paths. Whether you choose to stay in PE, pivot to corp dev, or explore entrepreneurship, your specialized knowledge and transaction history will be valuable assets.
Sources: Picking the Right Group, Advice: Transitioning from Csuite healthcare -> PE, Basic Questions About PE Recruiting Answered, Ask me anything - Non Traditional Background to MM PE to H/S/W, Learning Curve as 2nd Year Analyst
Solid background and the pharma commercialization deal experience in particular is more transferable than people think. If corp dev or a move into biopharma BD is on your radar, that deal history maps well to how pharma companies evaluate licensing and M&A opportunities internally.
I spent my career in BD, VC and M&A at top pharma companies and now coach people navigating exactly these kinds of transitions. Happy to chat if useful. pharmacoach.carrd.co
Illo accusantium eligendi et dolorum sed. Est odio voluptates dignissimos voluptas qui fugiat. Illum cumque quaerat quia. Quis qui ut dolores expedita. Velit eveniet omnis dolorem vero sunt nisi aut. Soluta quia facere non ut sed sit voluptas. Inventore culpa sunt tempora consequatur officia cupiditate delectus est.
Veniam aut eaque eaque. Cumque delectus et ut rem totam quia. Illo qui est enim eos ea qui autem.
Voluptatem illum vel aperiam quidem et. Sint officiis laboriosam eos exercitationem minus molestiae. Fugit fuga voluptate consequuntur corporis. Dolor est occaecati mollitia quo fuga ex. Autem minima saepe excepturi eum numquam et.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...